| Literature DB >> 24587866 |
Russell D White1, George D Harris1, Margaret E Gibson1.
Abstract
CONTEXT: Attention deficit hyperactivity disorder (ADHD) is common in the general population, and many individuals with this condition participate in sports activity at all competition levels. EVIDENCE ACQUISITION: Related studies were selected through literature searches of PubMed, MEDLINE, and Cochrane databases for the years 1991 to 2011. Key search terms were ADD, ADHD, sports, athletes, athletics, guidelines, NCAA, WADA, IOC, college, concussion, diagnosis, management, treatment, evaluation, return-to-play, pharmacotherapy, adult, adolescent, student, screening, injury, risk, neuropsychiatry, TBI, traumatic brain injury, and epidemiology. STUDYEntities:
Keywords: athletes; attention deficit; hyperactivity disorder
Year: 2014 PMID: 24587866 PMCID: PMC3931335 DOI: 10.1177/1941738113484679
Source DB: PubMed Journal: Sports Health ISSN: 1941-0921 Impact factor: 3.843
ADHD medications[67]
| Generic Name | Trade Name | Chemical Class | Comments | Side Effects | |
|---|---|---|---|---|---|
| Stimulants | Methylphenidate | Concerta, Ritalin, Metadate | Amphetamine | MOA: release and/or inhibit reuptake of D and NE | Decreased appetite, nervousness, weight loss, sleep difficulties, irritability, hypertension, tachycardia |
| Mixed dextroamphetamine- amphetamine salts | Adderall | Amphetamine | MOA: release and/or inhibit reuptake of D and NE | Decreased appetite, nervousness, weight loss, sleep difficulties, irritability, hypertension, tachycardia | |
| Dextroamphetamine | Dexedrin, Dextrostat (labeled Adderall in Canada) | Amphetamine | Not commonly used | Decreased appetite, nervousness, weight loss, sleep difficulties, irritability, hypertension, tachycardia | |
| Modafinil (“cognitive enhancer”) | Provigil | Wakefulness-promoting agent | MOA: possible alpha-1 agonist and inhibition of GABA release centrally | Hypertension, arrhythmias, tachycardia, syncope, nausea, diarrhea, headache, insomnia, nervousness | |
| Nonstimulants | Atomoxetine HCL | Strattera | Selective NE reuptake inhibitor | MOA: selective inhibition of the presynaptic NE transporter | Upset GI, sedation, fatigue, dry mouth, increased sweating, hypertension, rarely hepatotoxic, increased suicidality |
| Bupropion | Wellbutrin, Zyban | Aminoketon | MOA: D and NE reuptake inhibitor | Drowsiness, anorexia, tics, potential seizures | |
| Antidepressants | 1. Tofranil | Tricyclic | MOA: block reuptake of D and NE | Anticholinergic effects (eg, dry mouth, sweating abnormalities), ECG changes, drowsiness/sedation, increased suicidality | |
| Clonidine | Catapres | Alpha-2 agonist | MOA: alpha-2 agonists | Sedating postural hypotension, dry mouth, fatigue, dizziness, aggravation of preexisting cardiac arrhythmias, profound withdrawal effects |
MOA, mechanism of action; D, dopamine; NE, norepinephrine; GABA, γ-aminobutyric acid; HCL, hydrochloric acid; FDA, Food and Drug Administration; ECG, electrocardiogram.
Adapted with permission from the American Medical Society of Sports Medicine.[67]